Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK.
Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK
Eur Respir Rev. 2019 Sep 4;28(153). doi: 10.1183/16000617.0048-2019. Print 2019 Sep 30.
Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood, making the development of novel treatments challenging. Understanding the role bacteria play in disease progression has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing. The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial communities dominated by , and , while exhibiting intraindividual stability and large interindividual variability. and -dominated microbiomes have been shown to be linked to severe disease and frequent exacerbations. Studies completed to date are limited in size and do not fully represent all clinically observed disease subtypes. Further research is required to understand the microbiomes role in bronchiectasis disease progression. This review discusses recent developments and future perspectives on the lung microbiome in bronchiectasis.
支气管扩张症在全球的患病率正在增加，但目前可用的治疗方法仅限于缓解症状和减少恶化。该疾病的发病机制以及炎症、感染和疾病进展的分子驱动因素尚未完全阐明，这使得新型治疗方法的开发具有挑战性。下一代测序技术（如 16S rRNA 测序）的应用增强了对细菌在疾病进展中作用的理解。支气管扩张症中尚未对微生物组进行广泛研究，但现有数据表明，肺部细菌群落以 、 和 为主，同时表现出个体内稳定性和个体间变异性大。 和 主导的微生物组已被证明与严重疾病和频繁恶化有关。迄今为止完成的研究规模有限，不能完全代表所有临床观察到的疾病亚型。需要进一步研究以了解微生物组在支气管扩张症疾病进展中的作用。本文综述了支气管扩张症中肺部微生物组的最新进展和未来展望。
